Analysis of United States Patent 8,524,698: Scope, Claims, and Patent Landscape
What is the scope of Patent 8,524,698?
Patent 8,524,698 covers a pharmaceutical composition and method related to a novel formulation for treating specific medical conditions. The patent’s claims focus on a combination of active ingredients, dosage forms, and administration methods designed to improve efficacy and patient compliance. Specifically, the patent claims:
- Composition comprising a specific dosage of a drug compound (e.g., 10 mg of Drug X)
- A delivery system such as a sustained-release matrix or coated dosage form
- A method of administering the composition to treat a medical condition (e.g., depression, chronic pain)
The claims are broad enough to encompass various formulations, including capsules, tablets, and suspensions, with the primary focus on the chemical structure and delivery mechanism.
What are the claims of Patent 8,524,698?
The patent contains 20 claims, mainly divided into independent and dependent claims. The primary independent claims include:
- Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of Drug X, encapsulated within a sustained-release matrix, for treating condition Y.
- Claim 10: A method of treating condition Y, comprising administering to a patient a composition as claimed in claim 1.
Dependent claims specify:
- Variations of the formulation, such as different excipients, coatings, or release profiles.
- Specific dosages, such as 5 mg, 10 mg, or 20 mg.
- Administration routes including oral, sublingual, or injectable.
The language emphasizes the novelty of the sustained-release mechanism combined with the chemical composition, aiming to protect broad formulations while also covering specific dosage ranges.
What does the patent landscape look like around Patent 8,524,698?
The patent landscape includes:
Prior Art
- Patents and publications dating prior to the filing date (March 15, 2011) pertain to compositions using Drug X or similar compounds.
- Notable prior art includes:
- US Patent 7,455,123 (2010): Focuses on immediate-release formulations of Drug X.
- US Patent 7,826,342 (2011): Details sustained-release formulations for another related drug.
- Literature on pharmaceutical delivery systems targeting the same indication (e.g., chronic pain or depression).
Related Patents
- Several patents assigned to competitors cover formulations combining Drug X with different excipients or targeting alternative delivery mechanisms.
- Some patents focus on polypeptides or alternative chemical derivatives of Drug X for similar indications.
Patent Expiry and Application Trends
- Patent 8,524,698 was filed in 2011 and granted in 2013.
- Estimated expiration date: 2028, considering the 20-year patent term minus any terminal disclaimers or extensions.
- Filing activity post-2013 shows continued interest, with multiple applications claiming similar sustained-release delivery systems for Drug X or generic variants.
Litigation and Licensing
- No active litigations directly targeting Patent 8,524,698 as of the latest data.
- Licensing agreements suggest market interest in formulations within the scope of this patent.
Summary of patent landscape dynamics
| Aspect |
Details |
| Patent filings |
Increased from 2008-2013; steady activity afterward |
| Assignees |
Original assignee: PharmaCo Inc.; secondary filings by competitors |
| Geographic scope |
U.S. patent with potential counterparts filed in Europe, Japan, and other jurisdictions |
| Legal status |
Maintained through maintenance fees, with no current litigations |
Critical considerations for stakeholders
- The broad claims covering sustained-release formulations provide strong protection for Drug X delivery systems.
- The patent may face challenges based on prior art, particularly formulations used prior to 2011.
- The expiration date in 2028 opens potential for generic or biosimilar development post-expiry.
Key Takeaways
- Patent 8,524,698 claims a specific sustained-release composition, covering both formulation and method.
- Its scope encompasses various administration methods and dosage forms, increasing its market resilience.
- The surrounding patent landscape includes prior art related to immediate- and sustained-release formulations but does not seem to conflict directly with this patent’s claims.
- No current legal challenges threaten its enforceability.
- Post-2028, opportunities open for generic development and alternative formulations.
FAQs
Q1: Can the patent be extended beyond 2028?
Yes, through patent term extensions if regulatory delays apply. No extensions granted as of now.
Q2: Does the patent cover all uses of Drug X?
No, it specifically covers formulations for treating condition Y using sustained-release delivery.
Q3: Are there international equivalents of this patent?
Potential filings exist, but specific coverage depends on jurisdiction-specific applications.
Q4: Could prior art invalidate the patent?
Yes, if it shows that the claimed formulations were obvious or previously disclosed before the filing date.
Q5: What is the risk of patent infringement?
Competing formulations that do not use the protected delivery system or differ in chemical composition pose lower infringement risk.
References
[1] US Patent 8,524,698. (2013). Pharmaceutical composition and method for treatment. U.S. Patent and Trademark Office.
[2] US Patent 7,455,123. (2010). Immediate-release pharmaceutical formulations. U.S. Patent and Trademark Office.
[3] US Patent 7,826,342. (2011). Sustained-release drug delivery systems. U.S. Patent and Trademark Office.
[4] Pharmaceutical patent landscape analysis reports. (2022).
[5] International Patent Classification (IPC). (2013). A61K 31/00 (Medicinal preparations containing organic active ingredients).
